Literature DB >> 10223168

Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid.

R O Day1, A J McLachlan, G G Graham, K M Williams.   

Abstract

The major site of action for nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of rheumatic diseases is probably within the synovial compartment. There has been little work on the disposition of NSAIDs in the synovium and most studies have involved the measurement of their concentrations in synovial fluid. The concentrations of NSAIDs are more sustained in synovial fluid than in plasma, the difference being particularly noted with NSAIDs with short elimination half-lives. The more sustained concentrations may contribute to the prolonged effect of the short half-life NSAIDs, which are usually administered at intervals longer than their half-lives in plasma. The most widely used method of kinetic analysis of NSAIDs in synovial fluid is a compartmental model in which synovial fluid is a peripheral compartment of distribution of the drug. Repeated samples of synovial fluid from individual patients are difficult to collect, but even 1 sample of synovial fluid and plasma from each patient can provide useful data when analysed using the population approach to pharmacokinetic analysis. According to the compartmental model, the mean half-lives of efflux of the NSAIDs from synovial fluid range from 1.5 to 7 hours. The mean partition coefficient of most NSAIDs between synovial fluid and plasma is approximately 0.6. The NSAIDs are highly protein-bound, and the lower mean concentrations in synovial fluid are largely because of the lower concentrations of the binding protein, albumin. The NSAIDs diffuse into and out of synovial fluid in their unbound forms, but there is some diffusion in the protein-bound forms, particularly out of synovial fluid. The mean rates of diffusion of NSAIDs into and out of skin blisters in humans are similar to the rates of influx and efflux in the synovial fluid of the knee, but there is considerable variation between the pharmacokinetics of transfer at the 2 sites in individual patients. NSAIDs decrease the synthesis of prostaglandins in synovial fluid, but there are few data on the relationship between the kinetics of NSAIDs in synovial fluid and the effects on prostaglandin synthesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10223168     DOI: 10.2165/00003088-199936030-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  77 in total

1.  Stereoselective disposition of ibuprofen enantiomers in synovial fluid.

Authors:  R O Day; K M Williams; G G Graham; E J Lee; R D Knihinicki; G D Champion
Journal:  Clin Pharmacol Ther       Date:  1988-05       Impact factor: 6.875

2.  Integrated plasma and synovial fluid pharmacokinetics of tenoxicam in patients with rheumatoid arthritis and osteoarthritis: factors determining the synovial fluid/plasma distribution ratio.

Authors:  P H Hinderling; D Hartmann; C Crevoisier; U Moser; P Heizmann
Journal:  Ther Drug Monit       Date:  1988       Impact factor: 3.681

Review 3.  Articular pharmacokinetics of protein-bound antirheumatic agents.

Authors:  P A Simkin; M P Wu; D M Foster
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

4.  Effects of non-steroidal anti-inflammatory drugs and prednisolone on synovial fluid white cells, prostaglandin E2, leukotriene B4 and cyclic AMP in patients with rheumatoid arthritis.

Authors:  E Seppälä; M Nissilä; H Isomäki; H Wuorela; H Vapaatalo
Journal:  Scand J Rheumatol       Date:  1990       Impact factor: 3.641

5.  Pharmacokinetic and local tissue disposition studies of naproxen-following topical and systemic administration in dogs and rats.

Authors:  H Suh; H W Jun; M T Dzimianski; G W Lu
Journal:  Biopharm Drug Dispos       Date:  1997-10       Impact factor: 1.627

6.  Total and free ketoprofen in serum and synovial fluid after intramuscular injection.

Authors:  P Netter; B Bannwarth; F Lapicque; J M Harrewyn; A Frydman; J N Tamisier; A Gaucher; R J Royer
Journal:  Clin Pharmacol Ther       Date:  1987-11       Impact factor: 6.875

7.  Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations.

Authors:  R O Day; H Francis; J Vial; G Geisslinger; K M Williams
Journal:  J Rheumatol       Date:  1995-12       Impact factor: 4.666

8.  Osmosin: its effect on plasma and synovial fluid kinetics of indomethacin.

Authors:  P D Fowler; P T Dawes
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Sodium naproxen: concentration and effect on inflammatory response mediators in human rheumatoid synovial fluid.

Authors:  P Bertin; F Lapicque; E Payan; M Rigaud; F Bailleul; S Jaeger; R Treves; P Netter
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

10.  THE MANNER OF REMOVAL OF PROTEINS FROM NORMAL JOINTS.

Authors:  W Bauer; C L Short; G A Bennett
Journal:  J Exp Med       Date:  1933-02-28       Impact factor: 14.307

View more
  20 in total

1.  Pharmacokinetics of ketoprofen in rabbit after a single topical application.

Authors:  C Audeval-Gerard; C Nivet; A I el Amrani; P Champeroux; J Fowler; S Richard
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

2.  Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells.

Authors:  F Lapicque; P Vergne; J Y Jouzeau; D Loeuille; P Gillet; E Vignon; P Thomas; P Velicitat; D Türck; C Guillaume; A Gaucher; P Bertin; P Netter
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

3.  Effect of Disease-Related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats.

Authors:  Xiaonan Li; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2017-02-28       Impact factor: 3.922

4.  Modeling Sex Differences in Pharmacokinetics, Pharmacodynamics, and Disease Progression Effects of Naproxen in Rats with Collagen-Induced Arthritis.

Authors:  Xiaonan Li; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2017-02-28       Impact factor: 3.922

Review 5.  Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety.

Authors:  Nicholas Moore
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 6.  Using pharmacokinetic principles to optimize pain therapy.

Authors:  Kay Brune; Bertold Renner; Burkhard Hinz
Journal:  Nat Rev Rheumatol       Date:  2010-09-07       Impact factor: 20.543

7.  Development of a dog microdialysis model for determining synovial fluid pharmacokinetics of anti-arthritis compounds exemplified by methotrexate.

Authors:  Mingxin Qian; Wanda West; Jing-Tao Wu; Bing Lu; David D Christ
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

8.  "ChilDrive": a technique of combining regional cutaneous hypothermia with iontophoresis for the delivery of drugs to synovial fluid.

Authors:  Srinivasa M Sammeta; S Narasimha Murthy
Journal:  Pharm Res       Date:  2009-09-23       Impact factor: 4.200

9.  Pharmacokinetics of lumiracoxib in plasma and synovial fluid.

Authors:  Graham Scott; Christiane Rordorf; Christine Reynolds; Jyoti Kalbag; Michael Looby; Slavica Milosavljev; Margaret Weaver; John P Huff; Dennis A Ruff
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  The pharmacokinetics of the weakly protein-bound anionic compound diatrizoate in serum and synovial fluid of the horse.

Authors:  Anna Buus Frost; Frank Larsen; Susan Weng Larsen; Jesper Østergaard; Maj Halling Thomsen; Stefan Stürup; Pia Haubro Andersen; Claus Larsen
Journal:  Pharm Res       Date:  2009-10-30       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.